Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Giant Cell Tumor of Tendon Sheath 6Synovitis, Pigmented Villonodular 3Melanoma 2Glioblastoma 2Gastrointestinal Stromal Tumors 2Squamous Cell Carcinoma of Head and Neck 1Solid Tumors 1Solid Tumor 1Recurrence 1Prostatic Neoplasms 1Ovarian Neoplasms 1Leukemia, Myeloid, Acute 1Hodgkin Disease 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Advanced Solid Tumors 1

Interventions

Brentuximab Vedotin 27pembrolizumab 13Nivolumab 11Dacarbazine 8Vinblastine 7Doxorubicin 7Gemcitabine 6Bendamustine Hydrochloride 6plerixafor 5fludarabine 4Rituximab 4Granulocyte Colony-Stimulating Factor 4Cyclophosphamide 4Azacitidine 4abexinostat 3Melphalan 3Filgrastim 3Etoposide 3Busulfan 3Bleomycin 3umbralisib 2relatlimab 2pegfilgrastim 2mocetinostat 2itacitinib 2givinostat hydrochloride 2givinostat 2fludarabine phosphate 2durvalumab 2cc-486 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Hodgkin Disease × pexidartinib × Clear all
NCT01217229 2020-06-30

Safety and Efficacy Study of PLX3397 in Adults With Relapsed or Refractory Hodgkin Lymphoma

Daiichi Sankyo

Phase 2 Completed
20 enrolled 7 charts
Lymphoid

Hodgkin Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡